3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
30
Carcinoma, Non-Small-Cell Lung
9
Carcinoma, Hepatocellular
7
Breast Neoplasms
7
Carcinoma, Renal Cell
6
Lung Neoplasms
5
Ovarian Neoplasms
4
Colorectal Cancer Metastatic
3
Colonic Neoplasms
3
Adenocarcinoma of Lung
3
Rectal Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Liver Neoplasms
2
Financial Stress
2
Brain Neoplasms
2
Adenocarcinoma, Bronchiolo-Alveolar
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Unresectable Hepatocellular Carcinoma
1
Surgical Wound Infection
1
Non-Squamous Non-Small Cell Lung Cancer
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
NSCLC
1
Melanoma
1
Kidney Neoplasms
1
Hypertension
1
Hemorrhage
1
Glioblastoma
1
Feasibility
1
Interventions
tremelimumab
1
durvalumab
1
atezolizumab
1
Therapeutics
1
Immunotherapy
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Unresectable Hepatocellular Carcinoma
×
Bevacizumab
×
Clear all
NCT06117891
2026-05-12
REFINE-IO
Bayer
Active not recruiting
300 enrolled